tiprankstipranks
Trending News
More News >
Human Health Holdings Ltd. (HK:1419)
:1419
Hong Kong Market
Advertisement

Human Health Holdings Ltd. (1419) AI Stock Analysis

Compare
0 Followers

Top Page

HK:1419

Human Health Holdings Ltd.

(1419)

Rating:55Neutral
Price Target:
HK$1.00
▲(3.09%Upside)
The overall score reflects significant financial challenges with declining revenue and income, negatively impacting cash flow. While technical analysis indicates some positive momentum, the high RSI suggests caution. Valuation remains moderate with a reasonable P/E ratio and dividend yield, but financial instability could influence future performance.

Human Health Holdings Ltd. (1419) vs. iShares MSCI Hong Kong ETF (EWH)

Human Health Holdings Ltd. Business Overview & Revenue Model

Company DescriptionHuman Health Holdings Limited, an investment holding company, provides healthcare services in Hong Kong. The company offers general practice services, including general consultation, diagnostics and preventative health, minor procedure, vaccination, physical check-up, health education, occupational health advisory, Chinese medicine, work injury assessment, telemedicine, COVID-19 related, outreach services, and healthcare related services and products. It also provides specialty services in the areas of general surgery, orthopedics and traumatology, ophthalmology, otorhinolaryngology, pediatrics, obstetrics and gynecology, gastroenterology and hepatology, respiratory medicine, cardiology, pediatric surgery, dermatology and venereology, psychiatry, radiology, urology, nephrology, neurosurgery, anaesthesiology, and oncology, as well as physiotherapy, clinical psychology, medical aesthetics, nutritionist, health and wellness, endoscopy, and medical diagnostics. In addition, the company offers dental services comprising general dentistry, dental implant, 3D guided implant surgery, crown and bridge, periodontal treatment, prosthodontics, oral surgery, orthodontics, endodontics, cosmetic dentistry, teeth whitening, veneers and laser dentistry, advanced oral and maxillofacial surgery, CAD/CAM dentistry, panoramic radiography, and cone-beam computed tomography services. Further, it provides doctors and dentists agreements management, and medical imaging services. As of June 30, 2021, the company operated 58 medical centers and 103 service points. The company was founded in 1997 and is headquartered in Kowloon, Hong Kong. Human Health Holdings Limited is a subsidiary of Treasure Group Global Limited.
How the Company Makes MoneyHuman Health Holdings Ltd. generates revenue through its extensive network of medical centers by providing medical consultations, diagnostic testing, and health assessment services. The company's key revenue streams include fees for medical consultations and diagnostic services offered to both individual patients and corporate clients. Additionally, Human Health Holdings Ltd. partners with various insurance companies to offer services covered under health insurance plans, which contributes significantly to its earnings. The company also leverages its reputation and network to secure corporate health contracts, providing tailored healthcare solutions to businesses, which further enhances its revenue.

Human Health Holdings Ltd. Financial Statement Overview

Summary
Human Health Holdings Ltd. faces significant financial challenges with declining revenue and net income, impacting its income statement and cash flow. Despite a strong balance sheet with low leverage and strong liquidity, issues with negative free cash flow and reduced operating cash flow raise concerns about cash generation capabilities.
Income Statement
40
Negative
The income statement shows a concerning trend with declining revenues and profits over the past year. Revenue fell by approximately 41% from the previous year, and net income dropped by 87%. Gross profit margin stands at 45.7% and net profit margin at 4.1%, indicating the company's ability to manage costs relative to its revenue. However, the steep decline in both revenue and net income highlights significant financial challenges.
Balance Sheet
70
Positive
The balance sheet remains relatively strong, with a low debt-to-equity ratio of 0.19 and an equity ratio of 72.6%, indicating a solid financial foundation with low leverage. The company maintains a strong cash position, evidenced by a net debt of -343 million, suggesting a healthy liquidity buffer. Despite these strengths, the decline in stockholders' equity from the previous year is a concern.
Cash Flow
35
Negative
Cash flow analysis reveals significant issues, with free cash flow turning negative (-28 million) from a positive position in the previous year, indicating potential liquidity challenges. The operating cash flow to net income ratio is low, highlighting inefficiencies in converting profits into cash. The sharp decline in operating cash flow further exacerbates concerns about the company's cash generation capabilities.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue611.42M590.82M1.00B1.12B654.71M453.74M
Gross Profit279.63M269.85M593.24M659.68M376.69M189.84M
EBITDA37.19M104.06M323.46M513.25M238.36M42.16M
Net Income20.98M24.19M180.84M375.31M144.45M-40.37M
Balance Sheet
Total Assets1.03B1.06B1.26B1.16B612.39M427.99M
Cash, Cash Equivalents and Short-Term Investments479.84M489.58M641.26M270.33M162.83M137.19M
Total Debt132.16M146.46M182.49M188.47M67.08M102.17M
Total Liabilities258.48M289.71M455.27M416.67M202.26M168.94M
Stockholders Equity771.37M766.67M808.22M741.95M410.13M259.05M
Cash Flow
Free Cash Flow69.49M-28.17M580.24M219.30M71.44M26.03M
Operating Cash Flow85.25M11.34M664.26M295.81M85.49M37.50M
Investing Cash Flow201.63M-47.63M-335.34M-203.22M-4.77M-18.99M
Financing Cash Flow-73.29M-122.66M-178.28M-67.45M-59.30M-64.75M

Human Health Holdings Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.97
Price Trends
50DMA
0.83
Positive
100DMA
0.80
Positive
200DMA
0.79
Positive
Market Momentum
MACD
0.03
Negative
RSI
71.09
Negative
STOCH
83.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1419, the sentiment is Positive. The current price of 0.97 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.83, and above the 200-day MA of 0.79, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 71.09 is Negative, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1419.

Human Health Holdings Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
HK$384.46M9.125.95%9.79%0.81%27.55%
68
Neutral
HK$229.40M9.6010.72%4.46%-22.12%-28.95%
64
Neutral
HK$445.00M20.095.02%11.24%-15.22%-21.37%
61
Neutral
HK$635.35M38.231.07%4.68%-1.20%-87.51%
55
Neutral
HK$368.17M17.722.73%2.89%-0.69%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
51
Neutral
HK$146.55M-18.22%-56.16%62.50%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1419
Human Health Holdings Ltd.
0.95
-0.11
-10.38%
HK:8143
Good Fellow Healthcare Holdings Limited
0.12
-0.01
-7.69%
HK:2189
Kato (Hong Kong) Holdings Ltd.
0.44
-0.07
-13.73%
HK:2293
Bamboos Health Care Holdings Ltd
0.56
>-0.01
-1.75%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
1.90
-0.64
-25.20%
HK:0722
UMP Healthcare Holdings Limited
0.48
0.05
11.63%

Human Health Holdings Ltd. Corporate Events

Human Health Holdings Extends Limited Partnership Term Amid Market Challenges
Jun 25, 2025

Human Health Holdings Ltd. announced a further extension of the term for its investment in a Limited Partnership until June 30, 2026. This decision, made in light of challenging market conditions in the PRC, allows the company to explore better exit options without incurring additional management fees, which is considered beneficial for the company and its shareholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025